丙型肝炎病毒在肝细胞癌发生发展中的作用：从分子改变到可能的解决方案。
Responsibility of hepatitis C virus in the development of hepatocellular carcinoma: From molecular alterations to possible solutions.
作者信息
Bertino Gaetano, Malaguarnera Giulia, Frazzetto Evelise, Sciuto Alice, Inserra Gaetano, Zanghì Guido Nicola, Malaguarnera Michele
机构信息
Hepatology Unit, Department of Clinical and Experimental Medicine, University of Catania, Policlinico "G. Rodolico", Catania 95123, Italy.
Research Center "the Great Senescence", University of Catania, Catania 95100, Italy.
出版信息
World J Hepatol. 2018 Jun 27;10(6):448-451. doi: 10.4254/wjh.v10.i6.448.
Abstract
There are several causes of hepatocellular carcinoma (HCC), but certainly the hepatitis C virus (HCV) is one of the most common. The HCV is able to contribute, both directly and indirectly, to the development of HCC. Determining early HCV clearance before an advanced liver disease develops, is absolutely necessary as this prevents the initiation of the cascade of events induced by HCV that may result in the development of HCC. The early treatment of the infection and the clearance of HCV represents today, in the age of the direct antiviral agents (DAAs), an extraordinary opportunity for true prevention of the development of HCV-related HCC.
摘要
肝细胞癌（HCC）有多种病因，但丙型肝炎病毒（HCV）无疑是最常见的病因之一。HCV能够直接或间接促进HCC的发生。在晚期肝病发展之前确定HCV早期清除是绝对必要的，因为这可防止由HCV诱导的一系列事件的发生，而这些事件可能导致HCC的发展。在直接抗病毒药物（DAA）时代，对HCV感染进行早期治疗并清除病毒，为真正预防HCV相关HCC的发生提供了一个绝佳机会。
相似文献
1
Responsibility of hepatitis C virus in the development of hepatocellular carcinoma: From molecular alterations to possible solutions.丙型肝炎病毒在肝细胞癌发生发展中的作用：从分子改变到可能的解决方案。
World J Hepatol. 2018 Jun 27;10(6):448-451. doi: 10.4254/wjh.v10.i6.448.
2
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.直接作用抗病毒药物治疗的丙型肝炎相关肝硬化中肝细胞癌的早期发生和复发。
J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24.
3
Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.接受 DAA 治疗的晚期丙型肝炎患者新诊断的肝细胞癌：一项前瞻性人群研究。
J Hepatol. 2018 Aug;69(2):345-352. doi: 10.1016/j.jhep.2018.03.009. Epub 2018 Mar 16.
4
Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.与 HCV 感染直接作用抗病毒治疗的肝硬化患者新发或复发性肝细胞癌风险增加相关的因素。
Clin Gastroenterol Hepatol. 2019 May;17(6):1183-1191.e7. doi: 10.1016/j.cgh.2018.10.038. Epub 2018 Oct 26.
5
Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.肝细胞癌会降低使用直接作用抗病毒药物成功治疗丙型肝炎病毒的几率。
J Hepatol. 2017 Jun;66(6):1173-1181. doi: 10.1016/j.jhep.2017.01.020. Epub 2017 Feb 2.
6
Impact of hepatitis C virus eradication on hepatocellular carcinogenesis.丙型肝炎病毒根除对肝细胞癌发生的影响。
Cancer. 2015 Sep 1;121(17):2874-82. doi: 10.1002/cncr.29528. Epub 2015 Jun 16.
7
Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals.既往肝细胞癌史是慢性丙型肝炎病毒感染患者接受直接作用抗病毒药物治疗失败的独立危险因素。
J Viral Hepat. 2018 Dec;25(12):1462-1471. doi: 10.1111/jvh.12973. Epub 2018 Aug 30.
8
What Comes First: Treatment of Viral Hepatitis or Liver Cancer?先治肝炎还是先治肝癌？
Dig Dis Sci. 2019 Apr;64(4):1041-1049. doi: 10.1007/s10620-019-05518-5.
9
Interferon-alpha-induced hepatitis C virus clearance restores p53 tumor suppressor more than direct-acting antivirals.与直接作用抗病毒药物相比，干扰素α诱导的丙型肝炎病毒清除能更有效地恢复p53肿瘤抑制蛋白。
Hepatol Commun. 2017 Mar 28;1(3):256-269. doi: 10.1002/hep4.1025. eCollection 2017 May.
10
Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics.直接抗病毒药物治疗清除丙型肝炎病毒后肝细胞癌的风险：预测因素及表观遗传学的作用
Cancers (Basel). 2020 May 26;12(6):1351. doi: 10.3390/cancers12061351.
引用本文的文献
1
Serum Folate deficiency in HCV related Hepatocellular Carcinoma.血清叶酸缺乏与 HCV 相关的肝细胞癌。
Sci Rep. 2022 Mar 23;12(1):5025. doi: 10.1038/s41598-022-09030-1.
2
Improvement of health-related quality of life and psychological well-being after HCV eradication with direct-acting antiviral agents. Real life setting data of an Italian cohort valued by Hepatitis Quality of Life Questionnaire (HQLQv2).使用直接抗病毒药物根除丙型肝炎病毒后健康相关生活质量和心理健康状况的改善。一项意大利队列的真实生活数据，采用肝炎生活质量问卷（HQLQv2）进行评估。
Health Psychol Res. 2021 Jan 20;8(3):9450. doi: 10.4081/hpr.2020.9450. eCollection 2020 Dec 30.
3
Folate levels in hepatocellular carcinoma patients with portal vein thrombosis.肝癌合并门静脉血栓患者的叶酸水平。
BMC Gastroenterol. 2020 Nov 10;20(1):375. doi: 10.1186/s12876-020-01525-3.
本文引用的文献
1
Mechanism of action and efficacy of LY2109761, a TGF-β receptor inhibitor, targeting tumor microenvironment in liver cancer after TACE.TGF-β受体抑制剂LY2109761在TACE术后靶向肝癌肿瘤微环境的作用机制及疗效
Oncotarget. 2017 Dec 11;9(1):1130-1142. doi: 10.18632/oncotarget.23193. eCollection 2018 Jan 2.
2
Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection.丙型肝炎病毒感染诱发肝细胞癌的分子基础
World J Hepatol. 2017 Dec 28;9(36):1305-1314. doi: 10.4254/wjh.v9.i36.1305.
3
Evaluation of health status in patients with hepatitis c treated with and without interferon.评估使用和不使用干扰素治疗丙型肝炎患者的健康状况。
Health Qual Life Outcomes. 2018 Jan 17;16(1):17. doi: 10.1186/s12955-018-0842-x.
4
Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.直接作用抗病毒药物降低丙型肝炎病毒相关肝细胞癌初始治疗后的肿瘤复发率。
Dig Dis Sci. 2017 Oct;62(10):2932-2942. doi: 10.1007/s10620-017-4739-z. Epub 2017 Sep 7.
5
Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.丙型肝炎病毒（HCV）肝硬化患者接受直接抗病毒药物治疗会影响肝细胞癌的早期复发吗？一项前瞻性多中心研究。
Aliment Pharmacol Ther. 2017 Oct;46(7):688-695. doi: 10.1111/apt.14256. Epub 2017 Aug 9.
6
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.直接作用抗病毒药物治疗的 HCV 患者的肝细胞癌风险。
Gastroenterology. 2017 Oct;153(4):996-1005.e1. doi: 10.1053/j.gastro.2017.06.012. Epub 2017 Jun 19.
7
Lipoprotein(a) in patients with hepatocellular carcinoma and portal vein thrombosis.肝细胞癌合并门静脉血栓形成患者的脂蛋白(a)
Aging Clin Exp Res. 2017 Feb;29(Suppl 1):185-190. doi: 10.1007/s40520-016-0653-z. Epub 2016 Nov 7.
8
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.根治性切除或消融术后的肝细胞癌复发：HCV 清除的影响不依赖于干扰素的使用。
Aliment Pharmacol Ther. 2017 Jan;45(1):160-168. doi: 10.1111/apt.13821. Epub 2016 Oct 28.
9
Hepatocellular carcinoma and the risk of occupational exposure.肝细胞癌与职业暴露风险
World J Hepatol. 2016 May 8;8(13):573-90. doi: 10.4254/wjh.v8.i13.573.
10
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.接受无干扰素治疗的丙型肝炎相关 HCC 患者早期肿瘤复发率高。
J Hepatol. 2016 Oct;65(4):719-726. doi: 10.1016/j.jhep.2016.04.008. Epub 2016 Apr 13.
Zotero 插件